Inspire Medical Systems (INSP) Projected to Announce Quarterly Earnings on Monday

Inspire Medical Systems (NYSE:INSP) will likely be releasing its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect Inspire Medical Systems to announce earnings of $0.0870 per share and revenue of $204.31 million for the quarter. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Individuals can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 2, 2026 at 5:00 PM ET.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%. The firm had revenue of $200.58 million during the quarter, compared to analysts’ expectations of $194.72 million. During the same quarter last year, the business posted $0.45 EPS. The firm’s quarterly revenue was down 7.6% compared to the same quarter last year. On average, analysts expect Inspire Medical Systems to post $1.24 EPS for the current fiscal year and $1.54 EPS for the next fiscal year.

Inspire Medical Systems Trading Down 4.4%

Shares of INSP stock opened at $68.02 on Friday. The firm has a 50-day moving average price of $68.59 and a 200 day moving average price of $58.94. Inspire Medical Systems has a twelve month low of $38.91 and a twelve month high of $147.03. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of 31.36, a PEG ratio of 5.38 and a beta of 0.73.

Wall Street Analyst Weigh In

INSP has been the topic of several analyst reports. Piper Sandler raised their price target on shares of Inspire Medical Systems from $55.00 to $60.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Zacks Research lowered shares of Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 22nd. Robert W. Baird upped their price objective on shares of Inspire Medical Systems from $54.00 to $59.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Weiss Ratings raised shares of Inspire Medical Systems from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday. Finally, UBS Group started coverage on shares of Inspire Medical Systems in a research report on Tuesday, July 28th. They set a “sell” rating and a $39.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $68.82.

Insiders Place Their Bets

In related news, insider Jason Kelly sold 963 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $59.55, for a total transaction of $57,346.65. Following the transaction, the insider directly owned 18,985 shares in the company, valued at approximately $1,130,556.75. This represents a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 2.20% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.